Navigation Links
Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
Date:2/23/2009

MALVERN, Pa. and SHANGHAI, Feb. 23 /PRNewswire/ -- Frontage Laboratories Inc. ("Frontage"), a leading high quality provider of bioanalytical, pre-clinical, clinical and drug development services to global pharmaceutical companies, is pleased to announce it has expanded its research and development agreement with Beijing Second Pharmaceuticals, the ethical drug division of Beijing Pharmaceutical Group ("Beijing Pharma"), to accelerate Beijing Pharma's entrance into the international generic drug market. In addition, Frontage recently hired Len Stigliano as Chief Financial Officer and Derek (Yuanchao) Zhang, Ph.D. as Vice President of Regulatory Affairs and Clinical Pharmacology. These investments further strengthen Frontage's market leadership as a U.S.-China contract research organization.

The agreement with Beijing Pharmaceuticals is a further expansion of Frontage's current relationship with this client and its overall business in China. As part of the agreement, Frontage will obtain a newly constructed, 1,800 sq.meter R&D center and continued access to Beijing Pharma's GMP manufacturing areas. Frontage will also collaborate with Beijing Pharma to develop 12 ANDA products over the next 3-5 years, which will be marketed in China, Europe and the U.S. Frontage has been operating in China for 3 years, and serves both global and Chinese pharmaceutical customers. In 2007, Frontage helped Beijing Pharma in designing, renovating, and commissioning its manufacturing facilities to meet U.S. FDA and ICH GMP requirements, in building its GMP systems, employee training and in product development efforts. One of the products developed through the relationship has been filed to the U.S. FDA in 2008, with several more targeted for filing in 2009. European authorities successfully inspected the facilities in 2008.

"This partnership demonstrates our continued commitment to support the U.S., European and Chinese companies' develo
'/>"/>

SOURCE Frontage Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
2. Codexis Appoints Singapore Laboratories Managing Director
3. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
4. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
5. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
6. Stiefel Laboratories Appoints Two New Members to Board of Directors
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
8. ARUP Laboratories Releases ARUP Consult(R) 2.0
9. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
10. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
11. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... The Asian arthroscopic devices report defines and ... forecast of revenue. The arthroscopic devices market in Asia ... at a CAGR of 6.5% from 2013 to 2018. ... devices market, to get an idea of the in-depth ... segmentation of arthroscopic devices market in the same region, ...
(Date:10/18/2014)... October 18, 2014 The Asian Electronic Medical ... in Asian with analysis and forecast of revenue. The electronic ... grow to $2,328.0 million by 2018, at a CAGR of ... of the Asian Electronic Medical Record (EMR) market, to get ... a glimpse of the segmentation of the market in the ...
(Date:10/18/2014)... 2014 The report " Cloud ... Text; Web; Speech; Machine; Video; Predictive Analytics: Global ... Forecasts & Analysis (2013 - 2018) ", defines ... various sub segments with an in-depth analysis and ... the factors driving this market, various restraints, and ...
(Date:10/17/2014)... Alice,s journey through the looking-glass to Wonderland, mirrors in ... unexpected ways, including a new class of mirror that ... in The Optical Society,s (OSA) new high-impact journal ... first time, a new type of mirror that forgoes ... light by using an unusual magnetic property of a ...
Breaking Biology Technology:The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4
... Conference, SAN DIEGO, March 27 SGX Pharmaceuticals,(Nasdaq: ... the SGX523 clinical program., In January 2008, the ... SGX523 in patients with solid tumor cancers. The first,trial ... on a continuous,28-day cycle and the second trial has ...
... - GeneNews Limited (TSX: GEN),a company focused ... early,detection of diseases and personalized health management, ... fourth quarter and year ended,December 31, 2007., ... GeneNews because of the,advancements made for the ...
... Forms One of the Largest Sales Teams ... and PHILADELPHIA, March 26 /PRNewswire-FirstCall/,-- Shire plc ... company, announced today a co-promotion agreement with,TAP ... MMX(R),technology, indicated for the induction of remission ...
Cached Biology Technology:SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 2SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 3GeneNews announces 2007 year end results 2GeneNews announces 2007 year end results 3GeneNews announces 2007 year end results 4GeneNews announces 2007 year end results 5GeneNews announces 2007 year end results 6GeneNews announces 2007 year end results 7GeneNews announces 2007 year end results 8GeneNews announces 2007 year end results 9GeneNews announces 2007 year end results 10Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 2Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 3Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 4Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 5
(Date:10/16/2014)... be cultivated efficiently, they are anything but sustainable: ... monoculture cultivation is becoming increasingly evident. Despite their ... and are regarded as the sole possibility of ... wrongfully, finds Bernhard Schmid, an ecology professor at ... form of agriculture and forestry. After all, a ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... E or a combination of the supplements had a similar ... supplements, according to data from a randomized controlled trial in ... the National Cancer Institute. Epidemiological studies have suggested ... and thus antioxidants, may have a lower risk of cancer. ...
... has the honour of becoming the first student from ... competition that pitted engineering students and young professionals from ... the Institution of Engineering and Technology (IET), UK, the ... Mechanical & Aerospace Engineering beat three other contestants in ...
... Is Sensitive to Irradiation Researchers led by ... irradiation damages fat tissue. They report their findings in ... of Pathology . Radiation therapy directed ... of tissues such as fat tissue has often been ...
Cached Biology News:Vitamins C and E and beta carotene again fail to reduce cancer risk in randomized controlled trial 2NTU undergrad is first Singapore champion of an internationally acclaimed engineering competition 2NTU undergrad is first Singapore champion of an internationally acclaimed engineering competition 3Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5
...
... is a type I eukaryotic topoisomerase that ... (also called right- and left-handed supercoils) from ... reaction is a covalently closed, circular DNA ... DNA Topoisomerase I does not absolutely require ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Biology Products: